Connie G Chiu1, Simon K Chan2, Z Amy Fang3, Hamid Masoudi4, Richard Wood-Baker5, Steven J M Jones2, Blake Gilks6, Janessa Laskin7, Sam M Wiseman8. 1. Department of Surgery, St. Paul's Hospital, University of British Columbia, C303-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6. 2. Department of Medical Genetics, University of British Columbia and Michael Smith Genome Sciences Center, British Columbia Cancer Research Center, Vancouver, BC, Canada. 3. Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. 4. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. 5. Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada; Menzies Research Institute, Tasmania, Hobart, Tasmania, Australia. 6. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada. 7. Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada. 8. Department of Surgery, St. Paul's Hospital, University of British Columbia, C303-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6. Electronic address: smwiseman@providencehealth.bc.ca.
Abstract
INTRODUCTION: The objectives of this study were to determine the frequency and prognostic significance of beta-catenin expression in a cohort of non-small cell lung cancer (NSCLC) patients. METHODS: Tissue microarrays were constructed using clinically annotated formalin-fixed paraffin-embedded tumor samples from individuals diagnosed with NSCLC who underwent surgical resection with curative intent and had beta-catenin expression status determined by immunohistochemistry. RESULTS: Negative beta-catenin expression was seen in 28% (103/370) of NSCLC cases and was prognostic of a reduced overall patient survival (P = .008) and also was significantly correlated with the presence of lymphatic invasion (P = .015). In multivariate analysis, the loss of beta-catenin expression retained independent prognostic significance and showed an adjusted hazard ratio of 3.18 (confidence interval, 1.46-6.91, P = .004) for reduced patient survival when adjusting for the presence of lymphatic invasion, tumor grade, nodal status, and tumor stage. CONCLUSIONS: Beta-catenin represents an important prognostic marker in individuals diagnosed with surgically resectable NSCLC.
INTRODUCTION: The objectives of this study were to determine the frequency and prognostic significance of beta-catenin expression in a cohort of non-small cell lung cancer (NSCLC) patients. METHODS: Tissue microarrays were constructed using clinically annotated formalin-fixed paraffin-embedded tumor samples from individuals diagnosed with NSCLC who underwent surgical resection with curative intent and had beta-catenin expression status determined by immunohistochemistry. RESULTS: Negative beta-catenin expression was seen in 28% (103/370) of NSCLC cases and was prognostic of a reduced overall patient survival (P = .008) and also was significantly correlated with the presence of lymphatic invasion (P = .015). In multivariate analysis, the loss of beta-catenin expression retained independent prognostic significance and showed an adjusted hazard ratio of 3.18 (confidence interval, 1.46-6.91, P = .004) for reduced patient survival when adjusting for the presence of lymphatic invasion, tumor grade, nodal status, and tumor stage. CONCLUSIONS:Beta-catenin represents an important prognostic marker in individuals diagnosed with surgically resectable NSCLC.
Authors: Jiajia Jin; Ping Zhan; Masaru Katoh; Susumu S Kobayashi; Kevin Phan; Hong Qian; Huijuan Li; Xiaoxia Wang; Xihua Wang; Yong Song Journal: Transl Lung Cancer Res Date: 2017-02